Template:BNP value: Difference between revisions

No edit summary
 
(16 intermediate revisions by 4 users not shown)
Line 1: Line 1:
===[[Brain natriuretic peptide (BNP)]]===
===[[Brain natriuretic peptide (BNP)]]<ref>Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167. doi:10.1056/NEJMoa020233.</ref>===
*Biologically active metabolite of proBNP
*Measurement
*<100 pg/mL [[CHF]] ruled out (Sn 90%, NPV 89%)
**'''<100 pg/mL''': Negative for acute CHF (Sn 90%, NPV 89%)
*100-500: Consider differential diagnosis and pre-test probability
**'''100-500 pg/mL''': Indeterminate (Consider differential diagnosis and pre-test probability)
*> 500 Positive ([[CHF]] Sp 87%, PPV 90%)  
**'''>500 pg/mL''': Positive for acute CHF (Sp 87%, PPV 90%)
**Combination of BNP with clinician judgment 94% sensitive 70% specific (compared to 49% sn and 96% spec clinical judgement alone) <ref> McCullough et al. B-Type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation. 2002:DOI: 10.1161/01.CIR.0000025242.79963.4</ref>


===NT-proBNP<ref>Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb. 27(3):330-7.</ref><ref>Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005 Feb 17. 352(7):666-75.</ref><ref>Moe GW, Howlett J, Januzzi JL, Zowall H,. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007 Jun 19. 115(24):3103-10.</ref>===
===[[NT-proBNP]]<ref>Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb. 27(3):330-7.</ref><ref>Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005 Feb 17. 352(7):666-75.</ref><ref>Moe GW, Howlett J, Januzzi JL, Zowall H,. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007 Jun 19. 115(24):3103-10.</ref>===
*N-terminal proBNP
*<300 pg/mL [[CHF]] unlikely
*Biologically inert metabolite of proBNP
*[[CHF]] likely in:
*< 300 ng/mL, CHF unlikely
**'''>450 pg/mL''' in age < 50 years old
*CHF likely in:
**'''>900 pg/mL''' in 50-75 years old
**> 450 pg/mL in age < 50 yoa
**'''>1800 pg/mL''' in > 75 years old
**> 900 in 50-75 yoa
**> 1800 in > 75 yoa
 
====Differential Diagnosis (Elevated BNP)====
* [[CHF]]/[[ACS]]/[[Cardiogenic shock]]
* [[PE]]
* [[Pulmonary Hypertension]]
* [[Renal Failure]]
* [[LVH]]
* [[Subarachnoid hemorrhage]]
 
''May have false negatives with obesity and diastolic dysfunction''
 
====Utility====
*Obtaining BNP value may not add anything to patient centered outcomes<ref>Carpenter CR et al. BRAIN NATRIURETIC PEPTIDE IN THE EVALUATION OF EMERGENCY DEPARTMENT DYSPNEA: IS THERE A ROLE? J Emerg Med. 2012 Feb; 42(2): 197–205.</ref>
*May be used to gauge treatment response in acute decompensated CHF
 
===NT-proBNP<ref>Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb. 27(3):330-7.</ref><ref>Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005 Feb 17. 352(7):666-75.</ref><ref>Moe GW, Howlett J, Januzzi JL, Zowall H,. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007 Jun 19. 115(24):3103-10.</ref>===
*N-terminal proBNP
*Biologically inert metabolite of proBNP
*< 300 ng/mL, CHF unlikely
*CHF likely in:
**> 450 pg/mL in age < 50 yoa
**> 900 in 50-75 yoa
**> 1800 in > 75 yoa
 
====Differential Diagnosis (Elevated BNP)====
* [[CHF]]/[[ACS]]/[[Cardiogenic shock]]
* [[PE]]
* [[Pulmonary Hypertension]]
* [[Renal Failure]]
* [[LVH]]
* [[Subarachnoid hemorrhage]]
 
''May have false negatives with obesity and diastolic dysfunction''
 
====Utility====
*Obtaining BNP value may not add anything to patient centered outcomes<ref>Carpenter CR et al. BRAIN NATRIURETIC PEPTIDE IN THE EVALUATION OF EMERGENCY DEPARTMENT DYSPNEA: IS THERE A ROLE? J Emerg Med. 2012 Feb; 42(2): 197–205.</ref>
*May be used to gauge treatment response in acute decompensated CHF

Latest revision as of 21:51, 24 November 2019

Brain natriuretic peptide (BNP)[1]

  • Measurement
    • <100 pg/mL: Negative for acute CHF (Sn 90%, NPV 89%)
    • 100-500 pg/mL: Indeterminate (Consider differential diagnosis and pre-test probability)
    • >500 pg/mL: Positive for acute CHF (Sp 87%, PPV 90%)
    • Combination of BNP with clinician judgment 94% sensitive 70% specific (compared to 49% sn and 96% spec clinical judgement alone) [2]

NT-proBNP[3][4][5]

  • <300 pg/mL → CHF unlikely
  • CHF likely in:
    • >450 pg/mL in age < 50 years old
    • >900 pg/mL in 50-75 years old
    • >1800 pg/mL in > 75 years old
  1. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167. doi:10.1056/NEJMoa020233.
  2. McCullough et al. B-Type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from breathing not properly (BNP) multinational study. Circulation. 2002:DOI: 10.1161/01.CIR.0000025242.79963.4
  3. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb. 27(3):330-7.
  4. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005 Feb 17. 352(7):666-75.
  5. Moe GW, Howlett J, Januzzi JL, Zowall H,. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation. 2007 Jun 19. 115(24):3103-10.